Literature DB >> 15725191

Vaccination for birch pollen allergy: comparison of the affinities of specific immunoglobulins E, G1 and G4 measured by surface plasmon resonance.

C G Jakobsen1, U Bodtger, L K Poulsen, E L Roggen.   

Abstract

BACKGROUND: Allergen-specific immunotherapy (SIT) is associated with increased levels of allergen-specific IgG in serum. However, it is not clear to what extent qualitative changes in the allergen binding capacity of IgG may be induced as well.
OBJECTIVE: The purpose of this study was to investigate the influences of SIT on antibody affinity.
METHODS: The binding affinity of purified serum IgG1, IgG4 and IgE to the major allergen in birch (Betula verrucosa) pollen, Bet v 1, was analysed by surface plasmon resonance. The antibodies were obtained from 10 birch pollen-allergic patients receiving SIT and from 10 patients with no SIT.
RESULTS: The patients having received SIT have a significant higher titre of anti-Bet v 1 antibodies in their blood, but the affinity to Bet v 1 of allergen-specific IgE, IgG1 and IgG4 does not differ between the two groups. For IgG1 and IgG4, correlations between less allergic symptoms and affinity of the antibodies were observed both in the SIT group and to a smaller extent in the non-SIT group.
CONCLUSION: SIT has no effect on antibody affinity of allergen-specific IgE, IgG1 or IgG4. Allergic patients with high-affinity IgG1 and IgG4 antibodies report less symptoms than patients with low-affinity antibodies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15725191     DOI: 10.1111/j.1365-2222.2005.02160.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  9 in total

Review 1.  Pollen immunotherapy: selection,prevention, and future directions.

Authors:  Steven J McEldowney; Robert K Bush
Journal:  Curr Allergy Asthma Rep       Date:  2006-09       Impact factor: 4.806

Review 2.  Therapeutic manipulation of immune tolerance in allergic disease.

Authors:  Mübeccel Akdis; Cezmi A Akdis
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

3.  Changes in cat specific IgE and IgG antibodies with decreased cat exposure.

Authors:  Elizabeth A Erwin; Judith A Woodfolk; Hayley R James; Shama M Satinover; Thomas A E Platts-Mills
Journal:  Ann Allergy Asthma Immunol       Date:  2014-04-13       Impact factor: 6.347

Review 4.  Gender-medicine aspects in allergology.

Authors:  E Jensen-Jarolim; E Untersmayr
Journal:  Allergy       Date:  2008-05       Impact factor: 13.146

5.  Allergen-specific subcutaneous immunotherapy in allergic asthma: immunologic mechanisms and improvement.

Authors:  Yousef A Taher; Paul A J Henricks; Antoon J M van Oosterhout
Journal:  Libyan J Med       Date:  2010-06-21       Impact factor: 1.657

6.  Can Serum-Specific IgE/Total IgE Ratio Predict Clinical Response to Allergen-Specific Immunotherapy in Children Monosensitized to House Dust Mite?

Authors:  Gulbin Bingol Karakoc; Mustafa Yilmaz; Derya Ufuk Altıntaş; Seval Güneşer Kendirli
Journal:  J Allergy (Cairo)       Date:  2012-03-27

7.  Novel Approaches for Inhibiting the Indoor Allergen Der f 2 Excreted from House Dust Mites by Todomatsu Oil Produced from Woodland Residues.

Authors:  Yichun Lin; Christian Ebere Enyoh; Qingyue Wang; Senlin Lu; Wei Zhang; Kai Xiao; Shumin Zhou; Toshihiko Kaneko; Akifumi Seguchi; Weiqian Wang; Yue Guo
Journal:  Int J Environ Res Public Health       Date:  2022-08-31       Impact factor: 4.614

8.  Role of skin prick test in allergic disorders: a prospective study in kashmiri population in light of review.

Authors:  Roohi Rasool; Irfan Ali Shera; Saniya Nissar; Zaffar A Shah; Niyaz Nayak; Mushtaq A Siddiqi; Aga Syed Sameer
Journal:  Indian J Dermatol       Date:  2013-01       Impact factor: 1.494

9.  Does clinical outcome of birch pollen immunotherapy relate to induction of blocking antibodies preventing IgE from allergen binding? A pilot study monitoring responses during first year of AIT.

Authors:  Sara Huber; Roland Lang; Markus Steiner; Lorenz Aglas; Fatima Ferreira; Michael Wallner; Thomas Hawranek; Gabriele Gadermaier
Journal:  Clin Transl Allergy       Date:  2018-10-08       Impact factor: 5.871

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.